4'-chloro-7H-4,7'-bipyrrolo[2,3-d]pyrimidine
|
|
4'-chloro-7H-4,7'-bipyrrolo[2,3-d]pyrimidine 속성
- 끓는 점
- 397.4±52.0 °C(Predicted)
- 밀도
- 1.74±0.1 g/cm3(Predicted)
- 산도 계수 (pKa)
- 10.39±0.20(Predicted)
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
그림문자(GHS): | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
신호 어: | Warning | |||||||||||||||||||||||||||||||||||
유해·위험 문구: |
|
|||||||||||||||||||||||||||||||||||
예방조치문구: |
|
4'-chloro-7H-4,7'-bipyrrolo[2,3-d]pyrimidine C화학적 특성, 용도, 생산
4'-chloro-7H-4,7'-bipyrrolo[2,3-d]pyrimidine 준비 용품 및 원자재
원자재
준비 용품
4'-chloro-7H-4,7'-bipyrrolo[2,3-d]pyrimidine 공급 업체
글로벌( 55)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Hangzhou Huarong Pharm Co., Ltd. | 571-86758373 +8613588754946 |
sales@huarongpharm.com | CHINA | 3149 | 58 |
Nextpeptide Inc | +86-0571-81612335 +8613336028439 |
sales@nextpeptide.com | China | 19915 | 58 |
China National Standard Pharmaceutical Corporation Limited | +8615391658522 |
overseasales@yongstandards.com | China | 11927 | 58 |
ShenZhen H&D Pharmaceutical Technology Co., LTD | +86-0755-22677845 +86-13627253706 |
sale@hdimpurity.com | China | 3095 | 58 |
Amadis Chemical Company Limited | 571-89925085 |
sales@amadischem.com | China | 131980 | 58 |
ROSEWA HOLDING GROUP CO.,LIMITED | +86-023-62871537 |
sales@rosewachem.com | China | 2850 | 58 |
Shanghai Payne Pharmaceutical Technology Co.Ltd | 021-58123769 18678586262 |
info@paynepharm.com | China | 1354 | 58 |
BeiJing Hwrk Chemicals Limted | 0757-86329057 18934348241 |
sales4.gd@hwrkchemical.com | China | 14067 | 55 |
Wuhan ariel chemical Co., LTD. | 18986259541 18986259541 |
sales@3stc.com | China | 3965 | 58 |
Beijing Comparison Pharmaceutical Technology Co., Ltd | 15801002657 15701683040 |
sales@bjcomparison.com | China | 4749 | 58 |
4'-chloro-7H-4,7'-bipyrrolo[2,3-d]pyrimidine 관련 검색:
7H-Pyrrolo[2,3-d]pyrimidine, 4-hydrazinyl-
Tofacitinib impurity T
7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[(3R,4R)-4-methyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-3-piperidinyl]-
Tofacitinib Impurity 45
Ethyl S-4-chloro-3-hydroxybutyrate
2-amino-4-fluoro-5-nitrobenzoic acid
(3R,4R)-N,4-dimethyl-piperidin-3-amine
(3R,4R)-3-[(6-amino-4-pyrimidinyl)methylamino]-4-methyl-β-oxo-1-Piperidinepropanenitrile
(S)-N4-(3-chloro-4-fluorophenyl)-7-(tetrahydrofuran-3-yloxy)quinazoline-4,6-diaMine
Tofacitinib Impurity 20
R-afatinib
6,7-Dihydro-N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-5H-pyrrolo[2,3-d]pyrimidin-4-amine
3-((3R,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanaMide
3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
Tofacitinib Impurity 19
3-((3R,4R)-3-((2-chloro-7H-pyrrolo[2,3-d]pyriMidin-4-yl)(Methyl)aMino)-4-Methylpiperidin-1-yl)-3-oxopropanenitrile
N-((3R,4S)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
(3S,4S)-1-benzyl-N,4-diMethylpiperidin-3-aMine